Cyclacel Pharma (CYCC) Reports Q4 Loss of $0.10/Share

Cyclacel Pharma (NASDAQ: CYCC) reported Q4 EPS of ($0.10), versus ($0.21) reported last year. Revenue for the quarter came in at $424 thousand, versus $247 thousand reported last year.

For earnings history and earnings-related data on Cyclacel Pharma (CYCC) click here.

You May Also Be Interested In

• Micron offers Taiwan workers up to 68-month bonuses as strike threat looms
• Incyte (INCY) Reiterated at Neutral by Cantor Fitzgerald After Management Chat
• Piper Sandler picks Q2 Holdings as preferred stock in payments coverage